Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success by Schopka, Simon et al.
Schopka et al. Journal of Cardiothoracic Surgery 2010, 5:34
http://www.cardiothoracicsurgery.org/content/5/1/34
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Schopka et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Ablation of atrial fibrillation with the Epicor system: 
a prospective observational trial to evaluate safety 
and efficacy and predictors of success
Simon Schopka*, Christof Schmid, Andreas Keyser, Ariane Kortner, Julia Tafelmeier, Claudius Diez, Leopold Rupprecht 
and Michael Hilker
Abstract
Background: High intensity focused ultrasound (HIFU) energy has evolved as a new surgical tool to treat atrial 
fibrillation (AF). We evaluated safety and efficacy of AF ablation with HIFU and analyzed predictors of success in a 
prospective clinical study.
Methods: From January 2007 to June 2008, 110 patients with AF and concomitant open heart surgery were enrolled 
into the study. Main underlying heart diseases were aortic valve disease (50%), ischemic heart disease (48%), and mitral 
valve disease (18%). AF was paroxysmal in 29%, persistent in 31%, and long standing persistent in 40% of patients, 
lasting for 1 to 240 months (mean 24 months). Mean left atrial diameter was 50 ± 7 mm. Each patient underwent left 
atrial ablation with the Epicor system prior to open heart surgery. After surgery, the patients were treated with 
amiodarone and coumadin for 6 months. Follow-up studies including resting ECG, 24 h Holter ECG, and 
echocardiography were obtained at 6 and 12 months.
Results: All patients had successful application of the system on the beating heart prior to initiation of extracorporeal 
circulation. On average, 11 ± 1 ultrasound transducer elements were used to create the box lesion. The hand-held 
probe for additional linear lesions was employed in 83 cases. No device-related deaths occurred. Postoperative 
pacemaker insertion was necessary in 4 patients. At 6 months, 62% of patients presented with sinus rhythm. No 
significant changes were noted at 12 months. Type of AF and a left atrial diameter > 50 mm were predictors for failure 
of AF ablation.
Conclusion: AF ablation with the Epicor system as a concomitant procedure during open heart surgery is safe and 
acceptably effective. Our overall conversion rate was lower than in previously published reports, which may be related 
to the lower proportion of isolated mitral valve disease in our study population. Left atrial size may be useful to 
determine patients who are most likely to benefit from the procedure.
Background
Atrial fibrillation (AF) is the most commonly sustained
cardiac rhythm disorder. An estimated 4.5 million people
in the European Union and 2.2 million people in North
America suffer from paroxysmal or persistent AF [1]. All
types of AF are associated with a varying increased risk of
stroke and heart failure, and the overall mortality rate is
d o u b l e d  a s  c o m p a r e d  t o  p e o p l e  w i t h  n o r m a l  s i n u s
rhythm [2].
In cardiac surgery, the percentage of patients with con-
comitant AF is increasing because AF is linked to struc-
tural heart disease and the number of patients with
markedly advanced heart disease is growing. AF has also
been identified as an important risk factor for both mor-
tality and morbidity in cardiac surgery [3]. Recent studies
have shown that 10-year survival of patients undergoing
coronary bypass surgery without conversion of atrial
fibrillation into sinus rhythm is reduced by 24% [4].
Surgical treatment of AF began in 1987 with the Maze
procedure developed by Cox. Although the procedure
resulted in freedom from AF in 80% to 95% of patients
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after 15 years of follow-up, it was never widely accepted
because of its complexity and invasiveness [5]. Instead,
less extensive alternative treatment modalities utilizing
different energy sources for epi- or endocardial applica-
tion, such as radiofrequency, laser, microwave and cryo-
therapy, were devised to avoid the cut-and-sew technique
and to simplify surgery by creating a so-called box lesion
or pulmonary vein isolation [6]. Clinical studies analyzing
success rates of devices using these energy sources detect
success rates ranging from 65% to 90%, depending on the
energy source as well as patient characteristics and follow
up [6]. A particular problem of these new ablation tech-
niques is to create transmural lesions. T ransmurality is
considered essential but virtually impossible to control.
Accordingly, an exaggerated use of endocardial radiofre-
quency application has lead to damage at surrounding
structures, especially to esophageal injuries [7]. Epicar-
dial employment of high energy involves problems with
regard to the heat sink effect and energy propagation
through epicardial fat, and thus may also damage sur-
rounding structures [8]. In contrast, AF ablation with
high intensity focused ultrasound (HIFU) creates trans-
mural lesions without the need of large thermal gradients
and without jeopardizing adjacent structures (Figure 1)
[6].
The purpose of this study was to evaluate the efficacy of
left atrial HIFU ablation of AF with the Epicor Cardiac
Ablation System (St. Jude Medical, Maple Grove, MN) as
concomitant procedure during open heart surgery and to
assess predictors of success.
Materials and methods
Patients
From January 2007 to June 2008, 110 consecutive patients
scheduled for first-time open heart surgery and known
AF were prospectively enrolled into the study, which was
approved by the local ethic committee. Written informed
consent was obtained from all patients. The study cohort
included 66 men and 44 women with a mean age of 71.2
years (Table 1). Primary diagnosis was ischemic heart dis-
ease in 48%, aortic valve disease in 50%, and mitral valve
disease in 18% of patients. Twenty-five percent of
patients required combined cardiac surgery (Table 2).
Patients with ischemic heart disease were diagnosed with
paroxysmal AF in 38%, with persistent AF in 35%, with
longstanding persistent AF in 26% of cases, for patients
with aortic heart disease the percentage for the different
types of AF were 21% paroxysmal, 34% persistent, 43%
long standing persistent. Accordingly patients undergo-
ing combined cardiac surgery suffered in 20% of cases of
paroxysmal, in 37% of persistent, and in 41% of cases of
long standing persistent AF. There was no statistical sig-
nificant correlation in between type of AF and diagnosis
group. Preoperative left ventricular ejection fraction was
54.8 ± 9.6%, preoperative left atrial diameter was 50.2 ±
6.9 mm on average.
Diagnosis and classification of AF were established by
standard ECG and holter ECG in all patients prior to
admission. AF was defined paroxysmal in 29%, persistent
in 31% and long standing persistent in 40% of patients.
According to the Cox classification, AF was continuous in
71% and intermittent in 29% of patients. Atrial diameters
were significantly smaller in patients with intermittent
AF than in patients with continuous AF. 16 patients
underwent an ineffective attempt of rhythm control prior
to admission.
Surgical technique
In all patients, ablation of AF was performed via a midline
sternotomy prior to the initiation of extracorporeal circu-
lation for the subsequent cardiosurgical procedure.
The Epicor Positioning and Sizing (PAS) System, which
was designed to indicate the proper UltraCinch device
size and act as a guide for simple placement of the device
was passed behind the superior vena cava through the
transverse sinus and the oblique sinus underneath the
inferior vena cava. After measurement of the proper size,
the sizer was replaced by the UltraCinch ablation device
to create a "box" lesion above the ostia of all four pulmo-
nary veins. The two ends of the UltraCinch were approxi-
mated with tourniquets to snug the device securely
around the left atrium. After flushing of the transducer
elements with saline solution the ablation cycles were ini-
tiated and automatically progressed by the Epicor Abla-
tion Control System until completion. During the
Figure 1 Ultrasound ablated bovine myocardium. The scar shows 
a transmural lesion with the coronary vessels in the ablated section re-
maining patent. With permission of St. Jude Medical.Schopka et al. Journal of Cardiothoracic Surgery 2010, 5:34
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ablation process, that takes about 10 minutes, the surgical
preparations for extracorporeal circulation were contin-
ued. According to the surgeon's preference additional lin-
ear lesions were created with the UltraWand, particularly,
a mitral line that extends from the "box" lesion to the
mitral valve annulus.
Postoperative protocol
After surgery, all patients were treated with intravenous
heparin and amiodarone. With reconvalescence of the
patient, anticoagulation (warfarin or coumadin) and anti-
arrhythmic therapy (amiodarone 200 mg/d) were
switched to oral medication and maintained for 6
months. After 6 months continuance of oral anticoagula-
tion was determined on basis of the CHADS2 score. In
case of contraindications for amiodarone treatment, the
latter was replaced by a beta blocker, preferably sotalol. If
AF persisted or recurred external cardioversion/defibril-
lation was not recommended in the early postoperative
period to allow full maturation of the ablation line, which
takes up to three month in lesions created by ultrasound.
After 6 months Amiodarone was discontinued and
replaced by β-blockage.
A physical examination, standard 12-lead ECG, 24-
hour Holter monitoring, and transthoracic echocardiog-
raphy were conducted systematically at 6 and 12 month
follow-up visits.
Statistical analysis
Data were entered into a computerized database and ana-
lyzed with a statistical package (STATISTICA; StatSoft,
Inc). The descriptive summary of data included mean ±
standard deviation and 95% confidence intervals for con-
tinuous variables and proportions for categorical vari-
ables. Between-group differences were assessed with t-
tests and analysis of variance in more than two groups for
Table 1: Preoperative data of patients enrolled into the study.
Variable Mean SD Range
Age in years 71.8 7.5 48-86
AF duration in months 36.4 46.7 1-240
LA size 50.3 6.9 30 - 68
LVEF 54.8 9.7 27 - 70
EuroSCORE 7.6 6.6 0.9-43.9
Table 2: Procedures concomitantly conducted to left atrial epicardial ablation, absolute numbers and percentage of total
Procedure Number Percentage of Total
Isolated aortic valve repair/replacement 30 27%
Aortic valve + CABG 12
Isolated mitral valve repair/replacement 13 11%
Mitral valve + CABG 3
Isolated CABG 37 33%
Double valve surgery 12 10%
Tricuspid valve reconstruction 6
ASD closure 2
Ascending aorta replacement 3
Combined cardiac surgery 27 25%Schopka et al. Journal of Cardiothoracic Surgery 2010, 5:34
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continuous variables and Fishers exact tests for nominal
variables. The significance of variables on the odds of
procedure failure was assessed by univariate logistic
regression analyses. All reported p-values are two-sided.
Results
Safety evaluation
All patients had successful application of the system on
the beating heart prior to initiation of extracorporeal cir-
culation. On average, 11 ± 1 ultrasound transducer ele-
ments were used to create the box lesion. The hand-held
probe for additional linear lesions was employed in 83
cases. No device-related or procedure-related complica-
tions occurred, particularly no injury of the esophagus,
coronary arteries or, phrenic nerve. Within the 30-day
period, non-lethal postoperative complications including
temporary neurological dysfunction (cognitive disorder)
in 6 patients and mild pneumonia in 7 patients were
observed. Insertion of a long standing persistent pace-
maker was necessary in 4 patients who underwent aortic
valve replacement, combined with coronary bypass sur-
gery in 3 patients, and isolated in 1 patient. One patient
experienced an episode of atrial flutter 3 months after
surgery. and underwent successful interventional ablation
with subsequent stable sinus rhythm.
In-hospital, mortality was 3.6%. Two patients each died
of mediastinitis and of mesenterial ischemia and retro-
peritoneal bleeding, respectively. Three out of the 4
patients were > 70 years. The EuroSCORE of these
patients was 19.9 on average.
Evaluation of efficacy
All patients were alive at follow-up, complete data on car-
diac rhythm were obtained in 98% of cases. Mean follow-
up interval was 7.8 months, with 75 patients followed for
6 months and 49 patients for 12 months.
Overall freedom from AF, i.e. stable sinus rhythm, was
noted in 62% of patients at 6 months and 65% of patients
at 12 months after surgery, which was not significantly
different. Postoperative pacemaker stimulation for brady-
cardia remained necessary in 4 patients.
The influence of the concomitantly performed cardiac
procedure on the success rate of AF ablation of is
depicted in figure 2. Best results were obtained in
p a t i e n t s  u n d e r g o i n g  c o r o n a r y  a r t e r y  b y p a s s  s u r g e r y
(CABG), who presented with 69% freedom from AF at 6
months and a 81% freedom from AF at 12 months follow-
up (p = 0.47). Patients with aortic valve replacement dem-
onstrated a comparable outcome with 69% and 68% free-
dom from AF at 6 and 12 months, respectively (p = 1.0).
The patient population undergoing isolated mitral valve
surgery was too small for a valid comparison. Combined
cardiac surgery was associated with a much lower success
rate, with only 33% and 45% freedom from AF at 6 and 12
months, respectively (p = 0.69). In these patients, a larger
(preoperative) left atrial diameter was noted (as was also
seen in the mitral valve patients) compared to patients
with isolated ischemic heart disease or aortic valve dis-
ease (p = 0.019).
Preoperatively assessed parameters including type of
AF, duration of AF, left atrial diameter, left ventricular
e j e c t i o n  f r a c t i o n  a s  w e l l  a s  t h e  s i z e  o f  t h e  U l t r a C i n c h
ablation device (number of transducer elements) were
evaluated as predictors of success. The type of AF had a
profound impact on the success rate. At 12 months, sinus
rhythm was obtained in 100% of patients with paroxysmal
AF, in 58% of patients with persistent AF, and in 44% of
patients with long standing persistent AF (Figure 3). The
left atrial diameter measured by echocardiography was
highly predictive too. A cut-off point was seen at a diame-
ter of 50 mm (m-mode, parasternal long axis). Patients
with a left atrial diameter < 50 mm presented sinus
rhythm in 77% of cases, in contrast to patients with a left
Figure 2 Patients with sinus rhythm after undergoing CABG, aor-
tic valve disease and combined cardiac surgery at discharge, 6 
and 12 months follow-up.
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Figure 3 Percentage of patients with sinus rhythm or atrial fibril-
lation after 12 months follow-up dependent on preoperative left 
atrial size.
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atrial diameter > 50 mm, who had only a success rate of
41% (p = 0.0015) (Figure 4). Accordingly, a left atrial
diameter > 50 mm resulted in an odds-ratio of 4.2 (95%
confidence interval 1.88 to 12.64). Preoperative left ven-
tricular ejection fraction, size of the UltraCinch ablation
device, and duration of AF prior to surgery did not reveal
predictive value.
Discussion
AF as a common co-morbidity in cardiac surgical patients
with a prevalence of AF in about 10% of patients with
ischemic heart or aortic disease, and in almost 50% of
patients with mitral valve disease [9,10]. As uncorrected
AF is associated with increased morbidity and mortality
in patients undergoing cardiac surgery, AF ablation con-
comitant to cardiac surgery appears to be an efficient
measure to improve outcome.
The intention of this prospective study was to assess
safety of the Epicor ablation procedure and to identify
predictors for success and failure, respectively. Our study
population was not biased towards a positive selection. In
fact, every consecutive patient who wanted to participate
was included, which is also expressed by the average age
of 71 years and the EuroSCORE of 7.6. In contrast to pre-
vious reports, most of our patients suffered from isch-
emic heart disease and aortic valve stenosis, while only a
minority had mitral valve disease. Twenty-five percent of
patients underwent combined cardiac surgery. These
patients often have rather complex medical histories and
significant co-morbidity. If the cardiac surgery is
extended by ablation of AF, the latter procedure should
add only minimal risk to the patient. Ultrasound ablation
is a particularly appropriate intervention for these
patients since no bypass or cross clamp time is added to
the procedure. In contrast to an endocardial ablation,
atriotomy is not required as ultrasound is applied epicar-
dially on the beating heart. Accordingly, an Epicor abla-
tion may also be performed in off-pump CABG and as a
stand-alone procedure. A previous report from Ninet et
al. already stated an excellent safety of the system, which
is consistent with our experience. We did not observe any
procedure-related adverse event or postoperative compli-
cation, and the need for a postoperative pacemaker
implantation was low [6].
An appropriate postoperative management is impor-
tant after AF surgery. Since the maturation of the trans-
mural lesions and the electrical isolation of arrhythmic
foci may take up to 3 months, electrical cardioversion was
avoided during this period. Instead, patients were treated
with amiodarone to reduce the occurrence of arrhythmia
during the early phase after surgery [11,12]. As an evalua-
tion of success is not possible within the first 3 months,
the first follow-up visit was scheduled at 6 months after
surgery.
The overall freedom from AF with 65% was lower than
in previous publications with success rates of about 85%
[13,6]. This difference cannot be proven by less efficiency
of the ablation system since no interventional electro-
physiological studies could be performed during the fol-
low-up visits. However, one may speculate whether the
underlying heart diseases did also influence outcome.
Our patient cohort mainly suffered from ischemic heart
disease and aortic valve stenosis in contrast to previous
studies, where mitral valve disease was predominant
[6,13]. It is well known, that mere mitral valve surgery
(without additional AF ablation) had a significant benefi-
cial effect on conversion to sinus rhythm [14,15]. Accord-
ingly, in prior publications, success rates after ablation of
AF were typically superior in patients undergoing mitral
valve surgery [6]. A recent study on patients with isch-
emic heart disease has shown 77% freedom from AF,
which is comparable to our results [16].
As has also been shown by others, patients with parox-
ysmal AF showed a high success rate, significantly better
than those with persistent or long standing persistent AF
[6,13]. These patients usually suffer from less pathologic
alterations of the myocardium including myocyte size,
wall thickness, fibrotic changes and left atrial size.
Nevertheless, is should not be forgotten that these good
results may have been a result of inadequate diagnostic
measures to detect short periods of AF during follow-up
exams. Therefore, we now favor the implantation of event
recorders in patients who undergo AF ablation.
Our logistic regression analysis presented preoperative
LA size as the strongest predictor of the procedure's fail-
ure or success, respectively. At a cut-off point of 50 mm
failure rate dramatically worsened with an odd ratio of
4.2. The consequences of left atrial enlargement is less
well understood, but it has been assumed that the
Figure 4 Preoperative atrial fibrillation and percentage of pa-
tients with sinus rhythm postoperatively. Paroxysmal atrial fibrilla-
tion differs significantly from both persistent and long standing 
persistent atrial fibrillation, whereas no difference exists between per-
sistent and long standing persistent atrial fibrillation.
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arrhythmogenic foci known to trigger AF are then more
likely to reside in the left atrium than in pulmonary veins
[17,18]. In the literature, the duration of AF also showed
to have a predictive value but this could not be confirmed
in our analysis [6,7]. However , the duration of AF was
usually obtained via the medical history, which is of lim-
ited reliability because of the common occurrence of
asymptomatic AF.
The size of the transducer system, i.e. the number of
transducer elements, was not predictive too, and did not
correlate with echocardiographically measured left atrial
size.
In conclusion, we found the ultrasound epicardial abla-
tion of AF with the Epicor system, concomitantly applied
with cardiac surgery, to be a safe procedure. Effectiveness
of the ablation depends on the primary diagnosis as well
as on the preoperative left atrial size. Thus, these vari-
ables may serve as a tool to preoperatively identify
patients who are most likely to benefit from this proce-
dure. Further analysis of the Epicor registry, a multicenter
registry of patients undergoing ultrasound ablation, is
going to overcome the major limitation of the present
study, i.e. the low number of study participants.
Limitations of the study
The results of this study are limitated by the inhomoge-
nous study population, which is partly founded in the fact
that patients have been recruited consecutively. Another
limitation is the duration of follow up. The manuscript
presents data of the first 110 patients treated with this
device in the center, analysis of a multicenter registry will
follow. The most important limitation is the inhomoge-
nous usage of the additional device creating a mitral line,
further analysis will focus on regular usage of this device
and study its influence on freedom of AF.
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